Loading...

N4 Pharma is a pre-clinical stage specialist pharmaceutical company developing Nuvec®, a unique novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Established in 2014 and floated on the AIM stock market in May 2017.

Nuvec® is currently in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems.

Learn more

Watch our new video animation below to see Nuvec® in action:

Information for investors

For the latest regulatory news updates, information on the AIM rule 26, company presentations and reports

View investor information here

Latest news and updates

New corporate presentation – October 2024 

October 23rd, 2024|

Our new corporate presentation is now available to download. Listen to the video update from CEO, Nigel Theobald here. Key points covered in the presentation include:N4 Pharma's strategic focus on two key lead programs: N4 101 [...]